OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Internal Medicine is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis	327
Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease	173
Electrocardiographic features of patients with COVID-19 pneumonia	107
Incidence of acute pulmonary embolism in COVID-19 patients: Systematic review and meta-analysis.	102
SARS-CoV-2 vaccines: Lights and shadows	95
Mobile health technology-supported atrial fibrillation screening and integrated care: A report from the mAFA-II trial Long-term Extension Cohort	91
Hepatic consequences of COVID-19 infection. Lapping or biting?	81
Uric acid in metabolic syndrome: Does uric acid have a definitive role?	73
Low serum albumin: A neglected predictor in patients with cardiovascular disease	71
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study	67
Optimizing antibiotic therapies to reduce the risk of bacterial resistance	64
Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era	61
Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.	60
Factors associated with persistence of symptoms 1 year after COVID-19: A longitudinal, prospective phone-based interview follow-up cohort study	56
Mechanisms of weight regain.	55
The 2020 International Society of Hypertension global hypertension practice guidelines - key messages and clinical considerations	54
SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors	51
The Brain-Gut-Microbiotal Axis: A framework for understanding functional GI illness and their therapeutic interventions	48
Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management	47
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series	46
Prognostic impact of coronary microvascular dysfunction in patients with myocardial infarction with non-obstructive coronary arteries	45
The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later	44
Bleeding in COVID-19 severe pneumonia: The other side of abnormal coagulation pattern?	44
“Is medical cannabis safe for my patients?” A practical review of cannabis safety considerations	40
Beyond the 2020 guidelines on atrial fibrillation of the European society of cardiology	40

Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis	40
Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine	39
Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery	38
Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis	36
Consumer-led screening for atrial fibrillation using consumer-facing wearables, devices and apps: A survey of health care professionals by AF-SCREEN international collaboration	35
Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroente	34
COVID-19, vaccines and deficiency of ACE2 and other angiotensinases. Closing the loop on the "Spike effect"	34
How does SARS-CoV-2 targets the elderly patients? A review on potential mechanisms increasing disease severity	33
Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis	33